Prescription medicine
Hyaluronidase and pertuzumab and trastuzumab Brand names: Phesgo
Hyaluronidase and pertuzumab and trastuzumab (Phesgo) is a prescription medicine. No generic is listed in FDA's NDC Directory.
- No generic listed
- Boxed warning
Check it at the source: the hyaluronidase and pertuzumab and trastuzumab FDA label on DailyMed (effective May 21, 2026); every hyaluronidase and pertuzumab and trastuzumab label on DailyMed.
Highlights of the record
FDA label of May 21, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
CARDIOMYOPATHY, EMBRYO-FETAL TOXICITY,.
and PULMONARY TOXICITY WARNING: CARDIOMYOPATHY, EMBRYO-FETAL TOXICITY, and PULMONARY TOXICITY See full prescribing information for complete boxed warning. Cardiomyopathy: PHESGO administration can result in subclinical and clinical cardiac failure manifesting as CHF, and decreased LVEF, with greatest risk when administered concurrently with anthracyclines. Evaluate cardiac function prior to and during treatment. Discontinue PHESGO for cardiomyopathy. ( 2.3 , 5.1 ) Embryo-fetal Toxicity: Exposure to PHESGO can result in embryo-fetal death and birth defects. Advise patients of these risks and the need for effective contraception. ( 5.2 , 8.1 , 8.3 ) Pulmonary Toxicity: Discontinue PHESGO for anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome. ( 5.3 ) Cardiomyopathy PHESGO administration can result in subclinical and clinical cardiac failure. The incidence and severity were highest in patients receiving PHESGO with anthracycline-containing chemotherapy regimens. Evaluate cardiac function prior to and during treatment with PHESGO. Discontinue PHESGO treatment in patients receiving adjuvant therapy and withhold PHESGO in patients with metastatic disease for clinically significant decrease in left ventricular function [see Dosage and Administration (2.3) and Warnings and Precautions (5.1) ]. […]
Used for
From the label: indications and usagePHESGO is a combination of pertuzumab and trastuzumab, HER2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for: Use in combination with chemotherapy as: neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer.
Forms and strengths
- 600 mg/10ml / 600 mg/10ml / 10ml
- 1200 mg/15ml / 600 mg/15ml / 15ml
Injection (solution).
On the market
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
What is hyaluronidase and pertuzumab and trastuzumab used for?
From the label: indications and usagePHESGO is a combination of pertuzumab and trastuzumab, HER2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for: Use in combination with chemotherapy as: neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. […]
Conditions named in the indications of hyaluronidase and pertuzumab and trastuzumab's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Endoglycosidase and HER2/neu Receptor Antagonist.
Source: FDA drug label (Phesgo), Genentech, Inc., effective May 21, 2026 (SPL set 27dd5e6b-72cd-458d-a015-cf4dab5800da), via openFDA; the full label on DailyMed
Is there a generic for hyaluronidase and pertuzumab and trastuzumab (Phesgo)?
No generic hyaluronidase and pertuzumab and trastuzumab is approved (Drugs@FDA, October 8, 2026).
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What does the hyaluronidase and pertuzumab and trastuzumab label say about other medicines?
The hyaluronidase and pertuzumab and trastuzumab label names 2 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Docetaxel | warnings and precautions | An increased incidence of LVEF decline has been observed in patients treated with intravenous pertuzumab, intravenous trastuzumab, and docetaxel. |
| Doxorubicin | warnings and precautions | … serious cardiac arrhythmia requiring treatment or a cumulative prior anthracycline exposure to > 360 mg/m 2 of doxorubicin or its equivalent. |
Check hyaluronidase and pertuzumab and trastuzumab against other medicines
Source: FDA drug label (Phesgo), Genentech, Inc., effective May 21, 2026 (SPL set 27dd5e6b-72cd-458d-a015-cf4dab5800da), via openFDA; the full label on DailyMed
What else is labeled for the same conditions as hyaluronidase and pertuzumab and trastuzumab?
2 other medicines are given the same way (subcutaneous) and in the same FDA class as hyaluronidase and pertuzumab and trastuzumab or labeled mainly for the same use (breast cancer), the same class first. Breast cancer lists all 44 medicines labeled for it, by any route. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (subcutaneous) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Berahyaluronidase alfa and pembrolizumab | Breast cancer | none listed | n/a | No current entry |
| Goserelin | Breast cancer | none listed | n/a | No current entry |
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Other endoglycosidases
- the pharmacologic class, with prices and generics
- Check an interaction
- what two or more labels say about each other